REIT REITs mREITs image Log on |  Join ($$) Mortgage Real Estate Investment Trusts image Welcome, guest! Learn about guest access          
reits.valueforum.com
CENCORA INC (NYSE: COR)
Last Trade
4:00 p.m. - 356.94
Change
 2.09 ( 0.58%)
Shares Traded
32,179
Day's Volume
1,214,665
Book Value
NA
Price/Book
NA
Beta
0.2349
Day's Range
355.9023 - 363.50
Prev Close
359.03
Open
362.59
52 Wk Range
244.82 - 377.54
EPS
17.95
PE
19.89
Quarterly Div/Shr
0.66
Ex-Div
11/13/26
Yield
0.74%
Shares Out.
190.83M
Market Cap.
68.11B
  • 1 Year Stock Performance:

CAGR - Chart the growth of a $10K investment in COR

   Click here to search the Discussion Forum section for posts mentioning stock symbol COR »

Related news from
Mon, 16 Nov 2026
13:23:50 +0000
Are Wall Street Analysts Predicting Cencora Stock Will Climb or Sink?
Cencora has lagged behind the broader market over the past year, yet analysts remain highly optimistic about the stock’s prospects.
Fri, 13 Nov 2026
22:14:39 +0000
Update: FTC Sues to Block Covetrus' $3.5 Billion Acquisition of Cencora's MWI Veterinary Supply
(Updated to add Covetrus' comment in paragraph four.) Cencora (COR), the parent company of MWI Ve
Fri, 13 Nov 2026
17:20:00 +0000
Covetrus Issues Statement on FTC Decision to Challenge Proposed Merger with MWI Animal Health
Covetrus, a leading animal health technology, product and services company, today issued the following statement in response to the Federal Trade Commission's (FTC) decision to file a lawsuit to challenge Covetrus' proposed merger with MWI Animal Health (MWI), a subsidiary of Cencora.
Sun, 08 Nov 2026
21:25:36 +0000
Cencora’s Q3 CY2026 earnings call: our top 5 analyst questions
Cencora delivered calendar Q3 2026 results that aligned with market expectations on revenue and topped analyst profit forecasts. Management credited the quarter’s performance to strong growth in specialty pharmaceuticals, driven by recent acquisitions such as OneOncology and the expansion of its management services organization (MSO) platform. CEO Bob Mauch highlighted these investments as central to Cencora’s ability to support pharmaceutical-centric care, noting increased activity in specialty
Thu, 05 Nov 2026
22:12:14 +0000
Does Earnings Beat Change The Bull Case For Cencora (COR)?
Cencora reported fiscal Q4 2026 sales of US$88.35b and net income of US$519.4m, with full year earnings rising to US$3.48b, and increased its quarterly dividend to US$0.66 per share payable on 30 November 2026. The sharp shift from a prior year quarterly net loss to profit, combined with a higher dividend and new segment reporting, gives investors clearer visibility into how specialty services and acquisitions such as OneOncology contribute to Cencora's earnings profile. Next, the focus...
Thu, 05 Nov 2026
21:05:39 +0000
Cencora Inc (COR) (Q4 2026) Earnings Call Highlights: Record Fiscal 2026 Results, New ...
Cencora Inc (COR) delivered 12% adjusted EPS growth and $3.8 billion in free cash flow for fiscal 2026 while unveiling a two-segment structure and guiding fiscal 2027 adjusted EPS to $19.40--$19.75.
Thu, 05 Nov 2026
07:14:18 +0000
What Cencora (COR) Said on Its Q4 Earnings Call
Cencora (NYSE:COR) reported higher fiscal fourth-quarter revenue and adjusted earnings as specialty drug sales and its acquisition of OneOncology contributed to growth. The company also introduced a new reporting structure that separates its specialty operations from its broader pharmaceutical distr
Wed, 04 Nov 2026
18:48:22 +0000
Cencora (COR) Q4 2026 Earnings Call Transcript
Specialty biologics now drive over half of U.S. pharmaceutical spending.
Wed, 04 Nov 2026
18:34:15 +0000
Cencora, Inc. Q4 2026 Earnings Call Summary
Moby summary of Cencora, Inc.'s Q4 2026 earnings call
Wed, 04 Nov 2026
17:53:00 +0000
Cencora Q4 Earnings & Revenues Beat on Specialty Growth, Margins Expand
COR's Q4 earnings and revenues beat estimates as specialty drug demand fuels growth and margins expand. The company raises its fiscal 2027 outlook.
Wed, 04 Nov 2026
13:30:06 +0000
Cencora (COR) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Cencora (COR) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Thu, 05 Nov 2026
21:24:02 +0000
Drug Wholesalers Go Three-For-Three In Earnings Beats, But Only Two Stocks Pop
Drug distributors went three-for-three, with Cardinal Health putting up the last fall-quarter beat on Thursday, following the examples set by McKesson and Cencora.
Fri, 13 Nov 2026
23:02:02 +0000
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
Amgen trades at a lower forward P/E than Vertex, but Vertex's near-zero debt and cystic fibrosis dominance make the trade-off harder to call.
Tue, 10 Nov 2026
13:11:29 +0000
Can Cardinal Health Stock Repeat Its Last Five Years?
For questions about this article or underlying research, email help@trefis.com.
Fri, 06 Nov 2026
23:26:15 +0000
Is McKesson Stock Increasing Your Market Risk?
For questions about this article or underlying research, email help@trefis.com.
Fri, 06 Nov 2026
12:31:00 +0000
3 Stocks in Focus That Hiked Dividends Amid Ongoing Market Volatility
BDX, COR and UNF recently hiked dividends, offering investors steady income opportunities as market volatility, inflation and economic uncertainty persist.
Thu, 05 Nov 2026
21:17:27 +0000
The Biggest Drug Wholesaler Just Crushed Earnings Views — Here's What To Know
McKesson stock rose Thursday after the drug wholesaler topped fiscal second-quarter views and hiked its earnings guide.
Thu, 05 Nov 2026
16:39:19 +0000
What Just Happened To Medline Stock?
For questions about this article or underlying research, email help@trefis.com.
Thu, 05 Nov 2026
16:25:02 +0000
Amgen vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?
Amgen's growth engine and Pfizer's value appeal pull in opposite directions, and the valuation gap between them is wider than many expect.

If you are already a Value Forum member but are not logged on, click here to log on. If you are a guest, thank you for visiting ValueForum -- click here for information about guest access or click here to join -- a Trial Pass can be purchased for $6.99 to help you decide if you want to commit to longer term membership. Did you know there are customized portals into VF like REITs.ValueForum.com and also My ValueForum which lets you customize your VF experience to the posters and topics that most interest you!


"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "VF is a great group of value seeking investors, who are most generous in sharing their research, news, business expertise, and investment experience. It is an invaluable resource, and brings many 'lessons learned' to the group." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2026, Powered in part by Ticker Technologies • Contact Us

Cencora Inc (COR)